糖尿病血脂异常研究新进展

Update on the research of diabetic dyslipidemia

糖尿病血脂异常危害严重，但我国对该病的防治还不尽人意，临床实践与指南仍有较大差距。降低低密度脂蛋白胆固醇是糖尿病血脂异常防治的首要目标。生活方式调整和他汀类仍是糖尿病血脂异常治疗的基石，但在大剂量使用他汀类时应注意其不良反应，如肌酶的升高以及发生糖尿病风险的增加等。他汀类联合其他降脂药能否降低残留心血管风险，仍需进一步研究证实。

Dyslipidemia is one of the major risk factors for cardiovascular disease in diabetes mellitus, but clinical practices in the management of diabetic dyslipidemla are still not satisfactory in China. The cornerstone of treatment for diabetic dyslipidemia consists of therapeutic lifestyle change and statins. Recent guidelines emphasize aggressive low density lipoprotein-eholesterol control with statins. However, intensive statin therapy may increase the risk of myopathy and diabetes. Therefore, it is important to consider its risk-benefit ratio in individual patients. The additional benefit of statins in combination with other hypolipidemic drugs on cardiovascular risk needs verifying by further investigation.